If there’s one overarching theme that investors in biotech stocks should pay attention to in 2023, it’s “genetic medicine, genetic medicine, genetic medicine,” says Christopher Anzalone. Anzalone is biased, of course. He’s the chief executive of Arrowhead Pharmaceuticals (ARWR), a leader in a technology known as RNA interference, which turns off problem genes at the center of […]

Before most JPMers arose Monday morning, Ipsen announced that it is buying rare disease biotech Albireo Pharma. That’s the second deal disclosed Monday morning, along with AstraZeneca grabbing cardiovascular upstart CinCor Pharma. With the Chiesi-Amryt rare disease deal from Sunday night, that’s three M&A announcements to kick off the annual healthcare investment banking conference, albeit […]

In its 41 years, the annual J.P. Morgan Healthcare Conference has borne witness to innumerable shifts and evolutions across the healthcare landscape, including the explosion of Big Pharma’s power—and, alongside it, an explosion in drug pricing—as well as the biotech booms that have occurred practically every decade since the 1980s. With that massive increase in […]